Northwest Bio press releases called 'inappropriate,' The Street reports Dr. Aman Buzdar of MD Anderson Cancer Center, which is running the running the DCVax-Direct phase I/II clinical trial with funding from Northwest Biotherapeutics (NWBO), called the company's press releases "extremely unusual and inappropriate," The Street's Adam Feuerstein reports, citing a phone interview. Buzdar said MD Anderson and the two other hospitals conducting the DCVAX-Direct study are yet to review or analyze the trial data since patients are still being enrolled and treated. Shares of Northwest are trading down 10% to $8.11 in pre-open trading. Reference Link
Northwest Biotherapeutics files to delay Form 10-K The company requires additional time to complete its year end procedures. Those procedures could not be completed without incurring undue hardship and expense. The company undertakes the responsibility to file such annual report no later than fifteen days after its original date.